H. Lundbeck AS Ordinary Shares - Class B
HLUN B: XCSE (DNK)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| DKK 61.10 | Qrth | Jztflhchg |
Lundbeck's Strategic Brands Help Offset Generic Erosion Amid Upcoming Patent Losses
/s3.amazonaws.com/arc-authors/morningstar/ca9ef979-0207-4e37-b392-91618ebc1841.jpg)
Business Strategy and Outlook
Lundbeck focuses on central nervous system drugs, including antidepressants, antipsychotics, and antiepileptic products. While incremental innovations and label expansions have helped Lundbeck earn excess returns over the last several years, this was before many of Lundbeck’s patents reached their expirations. Since then, generic entry has created a lot of competition and pricing pressure for the company.